Roasted Bean Box Launches World’s First Data-driven Coffee Subscription in Montreal
Roasted Bean Box Launches World’s First Data-driven Coffee Subscription in Montreal Coffee lovers can get the flavors of the world customized to their exact taste preferences and delivered right to their door with Roasted Bean Box’s new subscription service. MONTREAL, April 27, 2021 (GLOBE NEWSWIRE) — Roasted Bean Box, a hot new subscription coffee delivery … Continue reading Roasted Bean Box Launches World’s First Data-driven Coffee Subscription in Montreal
AA Pharma Strengthens its Support of Canadian Clozapine Patients With Exclusive Rights to Blood Analyzer
AA Pharma Strengthens its Support of Canadian Clozapine Patients With Exclusive Rights to Blood Analyzer Health Canada Approval Enables Quick and Accurate Blood Testing TORONTO, April 27, 2021 /CNW/ – AA Pharma, a Canadian company focused on legacy pharmaceutical products, has secured the exclusive Canadian rights for the use of a blood analyzer for patients prescribed … Continue reading AA Pharma Strengthens its Support of Canadian Clozapine Patients With Exclusive Rights to Blood Analyzer
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel) Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell ALL and adult r/r DLBCL Alberta joins Quebec and Ontario to reimburse Kymriah therapy for these life-threatening … Continue reading Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure; TTI-621 monotherapy … Continue reading Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple … Continue reading Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
